person
as of 2026-07-01Michael Davidson, professor
Michael DavidsonMichael Davidson, MD
at a glance
Roles: Principal Investigator, Author, Investigator+Author
KOL signal score 11
3 publications · 1 high-value
Cross-drug reach: 1 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
Department of Psychiatry, Sackler Faculty of Medicine, Tel Aviv University, Israel
Roles
Principal Investigator, Author, Investigator+Author
KOL signal
11
Publications
3 (1 high-value)
Trial investigator
yes
Publishes on
1 drugs
Trials led
2
European Long-acting Antipsychotics in Schizophrenia Trial
NCT02146547Phase 4Completed
Publications & congress
3
Quality of life in early-phase schizophrenia patients starting treatment with long-acting injectable vs. oral antipsychotic drugs: Data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST).
European psychiatry : the journal of the Association of European Psychiatrists · 2026 · high-value
Negative symptoms in schizophrenia: Methodological challenges and emerging solutions for outcome measurement.
Neuroscience applied · 2026
Xanomeline/trospium and suicide-related events in schizophrenia: An early pharmacovigilance analysis.
Schizophrenia research · 2026
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here